Subtotal $0.00
Shop Now
Ozempic and pregnancy do not mix, according to the FDA labels. The Ozempic and Wegovy labels advise stopping semaglutide at least 2 months before a planned pregnancy because the drug takes weeks to leave the body. The weight-management labels for Wegovy and Zepbound say weight loss offers no benefit during pregnancy and may harm the fetus, so the medicine should be stopped when a pregnancy is recognized. Human data are limited: animal studies showed harm alongside maternal weight loss, while a large study of early-pregnancy exposure in women with type 2 diabetes did not find a large increase in birth defects. Reports of unexpected “Ozempic babies” are anecdotal. Anyone who could become pregnant should plan contraception and timing with a prescriber.
Peptide Labs does not sell Ozempic, Wegovy, Mounjaro, Zepbound or any prescription drug. This article summarizes FDA labels and published research. For the wider side-effect picture, see our guide to side effects across the GLP-1 class.
Key Takeaways
- Semaglutide labels advise stopping at least 2 months before a planned pregnancy.
- Wegovy and Zepbound labels say to stop when a pregnancy is recognized; weight loss offers no benefit.
- Tirzepatide may make birth control pills less effective; the labels advise a non-oral or backup method.
- Animal studies showed fetal harm, largely alongside maternal weight loss; human data are limited.
- A large cohort study did not find a large rise in birth defects after early exposure in type 2 diabetes.
- Wegovy and Zepbound have pregnancy registries for people exposed during pregnancy.
What the labels say about Ozempic and pregnancy
The Ozempic prescribing information (revised May 2026) says there are limited data on semaglutide in pregnant women. In animal studies, semaglutide given during organ formation caused embryo and fetal deaths, structural abnormalities and growth changes in rats, and early pregnancy losses or abnormalities in rabbits and monkeys. The label notes these findings coincided with marked weight loss in the mothers. Because Ozempic is a diabetes medicine, the label also stresses that poorly controlled diabetes in pregnancy raises risks for both mother and baby, and says Ozempic should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
The weight-management labels are firmer. The Wegovy label (June 2026) says weight loss offers no benefit to a pregnant patient and may cause fetal harm, and tells prescribers to stop Wegovy in pregnant patients using it for weight reduction. It adds that appropriate weight gain is recommended for all pregnant patients, including those with overweight or obesity. The Zepbound label (August 2026) uses the same reasoning and says to stop Zepbound when a pregnancy is recognized.
| Medicine | Planning a pregnancy | If pregnancy occurs | Breastfeeding | Label revision |
|---|---|---|---|---|
| Ozempic injection | Stop at least 2 months before | Use only if benefit justifies risk | No human data | May 2026 |
| Wegovy injection and tablets | Stop at least 2 months before | Stop if used for weight reduction | Tablets not recommended; no data for injection | June 2026 |
| Rybelsus and Ozempic tablets | Stop at least 2 months before | Use only if benefit justifies risk | Not recommended | January 2026 |
| Mounjaro | No set interval in the label | Use only if benefit justifies risk | Low or undetectable milk levels in a small study | August 2026 |
| Zepbound | No set interval in the label | Stop when pregnancy is recognized | Low or undetectable milk levels in a small study | August 2026 |
When to stop Ozempic before pregnancy
The Ozempic and Wegovy labels both tell people to stop Ozempic before pregnancy by at least 2 months, and the Rybelsus and Ozempic tablet label says the same. The reason is the long washout period. Semaglutide has a half-life of about a week, so it stays in the body for several weeks after the last use. Our article on how long Ozempic takes to work explains this half-life in more detail.
The Mounjaro and Zepbound labels do not give a specific interval for stopping before pregnancy. If you use tirzepatide and are planning a pregnancy, ask your prescriber when to stop. For people with type 2 diabetes, stopping a GLP-1 medicine usually means switching to another way of controlling blood sugar, which the Ozempic Medication Guide says to discuss with your healthcare provider before and during pregnancy.
Birth control on Mounjaro and Zepbound
The Mounjaro and Zepbound labels warn that tirzepatide may make oral hormonal contraceptives less effective because it delays stomach emptying, an effect that is largest after the first injection and fades over time. They advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each increase in strength. Our guide to diarrhea on GLP-1 medicines covers this warning alongside the digestive side effects. The semaglutide labels do not carry the same contraceptive advice, but vomiting or severe diarrhea from any cause can affect the pill, so ask a pharmacist if that happens.
Ozempic babies: what is behind the reports
“Ozempic babies” is a social media term for unplanned pregnancies reported by people taking GLP-1 medicines. There are no published studies counting these pregnancies, so it is not known how common they are or whether they happen more often than expected. Two explanations are plausible but unproven:
- Weight loss and ovulation. The National Institute of Child Health and Human Development says that in people with polycystic ovary syndrome (PCOS) and overweight, weight loss can restore ovulation and make cycles more regular, which can improve the chances of pregnancy.
- Birth control pills on tirzepatide. As described above, the Mounjaro and Zepbound labels say oral contraceptives may work less well, especially early on and after each increase in strength.
Neither explanation has been confirmed for GLP-1 users as a group. If you do not want to become pregnant, the practical step is to review contraception with your prescriber before starting a GLP-1 medicine, not after.
What happens if you get pregnant on Ozempic or Wegovy?
Tell your prescriber as soon as you know. The Wegovy label says pharmacovigilance and trial data are insufficient to establish a drug-related risk of birth defects, miscarriage or other adverse outcomes. For context, the labels give the background U.S. risk in recognized pregnancies as 2% to 4% for major birth defects and 15% to 20% for miscarriage.
The largest human study so far, published in JAMA Internal Medicine in 2024, used data from four Nordic countries, the United States and Israel. Among infants of women with type 2 diabetes, 938 had been exposed to a GLP-1 medicine from 90 days before pregnancy through the first trimester. Compared with insulin, the adjusted relative risk of major birth defects was 0.95 (95% CI 0.72 to 1.26). The authors called the result reassuring but imprecise and said confirmation is needed. The study looked at birth defects only, not every pregnancy outcome, and received National Institutes of Health funding.
Novo Nordisk runs a Wegovy pregnancy registry and Eli Lilly runs a Zepbound pregnancy registry, which collect health information from people exposed during pregnancy. Your prescriber can explain how to take part. Registry data help fill the gaps that trials leave, since trials generally exclude pregnant people.
Breastfeeding on GLP-1 medicines
There are no human data on injected semaglutide in breast milk; it was found in the milk of lactating rats. For the tablet forms (Wegovy tablets, Rybelsus and Ozempic tablets), the labels say breastfeeding is not recommended because the absorption enhancer SNAC passes into milk and could build up in infants. For tirzepatide, a single-use study in 11 lactating women found the drug undetectable in 164 of 171 milk samples, but there are no data on effects in breastfed infants. The labels ask prescribers to weigh the benefits of breastfeeding against the mother’s need for the medicine.
For other effects that matter when planning a family, such as nausea and gallbladder problems, see our guides to semaglutide side effects and tirzepatide side effects. The thyroid warning shared by all these medicines is explained in our guide to the boxed warning.
Frequently Asked Questions
Can you take Ozempic while pregnant?
The labels advise against it. Ozempic should be used in pregnancy only if the benefit justifies the risk, and Wegovy and Zepbound should be stopped when a pregnancy is recognized.
How long before pregnancy should I stop Ozempic?
The Ozempic and Wegovy labels say at least 2 months before a planned pregnancy, because semaglutide takes weeks to clear. The tirzepatide labels do not set an interval, so ask your prescriber.
What should I do if I get pregnant on Wegovy?
Contact your prescriber promptly. The label says to stop Wegovy used for weight reduction, and a Wegovy pregnancy registry collects outcome information.
Are Ozempic babies real?
Unplanned pregnancies on GLP-1 medicines are reported online, but no published study has measured how often they occur. Weight loss restoring ovulation is one plausible explanation.
Does Zepbound affect birth control pills?
Yes, the label says it may make oral contraceptives less effective and advises a non-oral or backup method for 4 weeks after starting and after each increase in strength.
Can I breastfeed while taking Ozempic?
There are no human data for the injection. The labels say breastfeeding is not recommended with the semaglutide tablets. Discuss feeding choices with your prescriber.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: GLP-1 Side Effects: What Every GLP-1 Drug Label Warns About, Ozempic Diarrhea: How Common It Is and When to Call, Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say.